These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 9072585)

  • 1. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
    Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
    Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
    Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
    J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
    Brada M; Horwich A; Peckham MJ
    Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
    Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
    J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
    Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
    Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of good risk germ-cell tumours.
    Troost MM; Sternberg CN; de Wit R
    BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
    Kondagunta GV; Bacik J; Bajorin D; Dobrzynski D; Sheinfeld J; Motzer RJ; Bosl GJ
    J Clin Oncol; 2005 Dec; 23(36):9290-4. PubMed ID: 16361627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
    Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
    J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for good risk germ cell tumors.
    McCaffrey JA; Bajorin DF
    Semin Oncol; 1998 Apr; 25(2):186-93. PubMed ID: 9562451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.